Navigation Links
Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients
Date:3/23/2009

Xarelto Will Earn Decision Resources' Clinical Gold Standard Status for VTE Prophylaxis in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., March 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists indicate that a therapy's effect on the prevention of venous thromboembolism (VTE) is the attribute that most influences their prescribing decisions for VTE prophylaxis in medically ill patients. Clinical data and the opinions of interviewed thought leaders indicate that Bayer/Johnson & Johnson's Xarelto has advantages in this attribute over Sanofi-Aventis's Lovenox, the sales-leading agent in the market.

The new report entitled Venous Thromboembolism Prophylaxis in Medically Ill Patients: Significant Opportunity Awaits Therapies Offering Improved Efficacy finds that an orally available therapy for VTE prophylaxis in medically ill patients would earn a 65 percent patient share in the United States and an 80 percent patient share in Europe, according to surveyed U.S. and European cardiologists.

In 2008, Decision Resources' proprietary clinical gold standard for VTE prophylaxis in medically ill patients was GlaxoSmithKline's Arixtra, owing largely to its efficacy. Based on available data and expert opinion, Xarelto will earn gold standard status for VTE prophylaxis in medically ill patients in 2012, following its approval for the indication in 2011.

"Xarelto has competitive advantages over Arixtra in terms of delivery and safety," said Decision Resources Analyst Christine Helliwell, Ph.D. "Xarelto's main advantage is that it causes a level of bleeding similar to that of Lovenox, whereas Arixtra suffers from a perception that it causes increased rates of bleeding over Lovenox."

About the Report

Venous Thromboembolism Prophylaxis in Medically Ill Patients: Significant Opportunity Awaits Therapies Offering Improved Efficacy is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                      Decision Resources, Inc.
    Christopher Comfort                     Elizabeth Marshall
    781-296-2597                            781-296-2563
    ccomfort@dresources.com                 emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
2. As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
3. Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes
4. Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohns Disease
5. Half of Full-Time Employees Surveyed Dont Understand Health Insurance Coverage for Cancer-Related Medical Expenses
6. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
7. Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugais Actemra for Rheumatoid Arthritis
8. World Vision Index of Concern: Half of Americans Surveyed Said They Would Be Willing to Pay More Taxes to Combat AIDS
9. Experts from Africa and Asia to Discuss Maternal Health in Live Online Chat
10. FDA Experts to Speak at RAPS Horizons Conference
11. In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
Breaking Medicine Technology: